TransCode Therapeutics, Inc (RNAZ) Prices 6.25M Share IPO at $4/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- S&P 500, Nasdaq futures inch up as markets monitor Hormuz situation
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil edges higher as Iran tempers hopes of swift Hormuz reopening
- HPE stock surges 5% as Morgan Stanley upgrades, pointing to ~30% upside
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering
July 8, 2021 6:34 PM EDTBOSTON--(BUSINESS WIRE)-- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company") an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $4.00 per share, for gross proceeds of $25,000,000, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 937,500 shares of common stock to cover... More
